ImmunityBio Current Ratio Growth & History (IBRX)

ImmunityBio's current ratio was 5.10 for fiscal 2025.

View full ImmunityBio company overview

ImmunityBio annual current ratio history

ImmunityBio annual current ratio

Fiscal yearPeriod endedCurrent ratioChangeGrowth
20252025-12-315.101.74+51.77%
20242024-12-313.36−1.69−33.42%
20232023-12-315.054.77+1697.76%
20222022-12-310.28−0.63−69.02%
20212021-12-310.91−0.73−44.74%
20202020-12-311.64
20182018-12-313.26−3.09−48.70%
20172017-12-316.35−9.99−61.16%
20162016-12-3116.34−32.05−66.23%
20152015-12-3148.4016.88+53.57%
20142014-12-3131.51

ImmunityBio current ratio trends

Over the last five fiscal years, ImmunityBio's current ratio increased from 1.64 to 5.10, a change of 3.46. The latest reported quarter, Q2 2026, shows 5.72.

About the metric

What the current ratio means

The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.

Calculation and source

How the current ratio is calculated

TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review ImmunityBio source filings ↗

Community posts

It’s quiet here.

No posts about IBRX yet. Start the conversation.

Write the first post